Home

Kolac strast Staviti zajedno gilead medicine Soping centar studija hipoteza

Gilead reaches multiyear agreement with White House to donate PrEP
Gilead reaches multiyear agreement with White House to donate PrEP

Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS

FDA approves Gilead's multi-drug resistant HIV-1 treatment
FDA approves Gilead's multi-drug resistant HIV-1 treatment

Gilead Revenue Soars on Hepatitis C Drug - The New York Times
Gilead Revenue Soars on Hepatitis C Drug - The New York Times

Gilead to Slice List Prices of Liver Drugs - WSJ
Gilead to Slice List Prices of Liver Drugs - WSJ

Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut
Study: To be cost-effective, Gilead's new HIV pill needs near-50% price cut

New Data On Gilead's Covid-19 Drug Is Positive, but Inconclusive | Barron's
New Data On Gilead's Covid-19 Drug Is Positive, but Inconclusive | Barron's

Pharma giant Gilead sued for 'withholding' safer HIV drug | PinkNews
Pharma giant Gilead sued for 'withholding' safer HIV drug | PinkNews

Gilead bags EU approval for next-generation HIV drug - PMLiVE
Gilead bags EU approval for next-generation HIV drug - PMLiVE

Gilead reports 3% revenue growth in Q1 2022
Gilead reports 3% revenue growth in Q1 2022

Gilead Wins Key Patent Rights Suit Over PrEP Drugs for Preventing HIV - The  New York Times
Gilead Wins Key Patent Rights Suit Over PrEP Drugs for Preventing HIV - The New York Times

Sovaldi: Who's to Blame for the $1,000 a Day Cure? - Knowledge at Wharton
Sovaldi: Who's to Blame for the $1,000 a Day Cure? - Knowledge at Wharton

Gilead loses monopoly control of its blockbuster hepatitis C medicine in  China | Médecins Sans Frontières Access Campaign
Gilead loses monopoly control of its blockbuster hepatitis C medicine in China | Médecins Sans Frontières Access Campaign

Gilead drug remdesivir shows promise in two coronavirus trials
Gilead drug remdesivir shows promise in two coronavirus trials

Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back  Reimbursement To 340B Providers :: Pink Sheet
Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers :: Pink Sheet

United States v. Gilead: The Fight for PrEP | Bill of Health
United States v. Gilead: The Fight for PrEP | Bill of Health

PrEP's Still Too Costly For Many People At Risk For HIV : Shots - Health  News : NPR
PrEP's Still Too Costly For Many People At Risk For HIV : Shots - Health News : NPR

Trump administration sues Gilead over HIV drugs
Trump administration sues Gilead over HIV drugs

Gilead's Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline  strikes back | Fierce Pharma
Gilead's Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline strikes back | Fierce Pharma

Examining the Truvada #BreakThePatent Debate: Gilead Responds
Examining the Truvada #BreakThePatent Debate: Gilead Responds

Gilead to launch generic versions of hepatitis C drugs | Modern Healthcare
Gilead to launch generic versions of hepatitis C drugs | Modern Healthcare

Gilead Advancing Access®: What to Know | Prism Health North Texas
Gilead Advancing Access®: What to Know | Prism Health North Texas

Gilead Revenue Soars on Hepatitis C Drug - The New York Times
Gilead Revenue Soars on Hepatitis C Drug - The New York Times

Gilead prices remdesivir at $2,340 per patient for developed countries
Gilead prices remdesivir at $2,340 per patient for developed countries

Untangling the Trump administration's lawsuit over an HIV prevention drug |  Science | AAAS
Untangling the Trump administration's lawsuit over an HIV prevention drug | Science | AAAS